Incidence of local recurrence in relation to radiotherapy and trastuzumab in early Her2 positive breast cancer

被引：0
|
作者：
Traa, F. [1 ]
Vane, M. [1 ]
Van Roozendaal, L. [2 ]
Heuts, E. [1 ]
Siesling, S. [3 ]
Moossdorff, M. [2 ]
Smidt, M. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Surg, Maastricht, Netherlands
[2] Zuyderland Med Ctr, Surg, Heerlen, Netherlands
[3] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Hlth Technol & Serv Res, Enschede, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
368 (PB-16
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [21] Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab in HER2 positive metastatic or locally recurrent unresectable breast cancer: assessment of toxicity
    Ajgal, Z.
    De Percin, S.
    Loirat, D.
    Pierga, J. Y.
    Campana, F.
    Fourquet, A.
    Kirova, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S50 - S51
  • [22] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [23] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Caroline Rönnlund
    Emmanouil G. Sifakis
    Caroline Schagerholm
    Qiao Yang
    Emelie Karlsson
    Xinsong Chen
    Theodoros Foukakis
    Jodi Weidler
    Michael Bates
    Irma Fredriksson
    Stephanie Robertson
    Johan Hartman
    Breast Cancer Research, 26
  • [24] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Ronnlund, Caroline
    Sifakis, Emmanouil G.
    Schagerholm, Caroline
    Yang, Qiao
    Karlsson, Emelie
    Chen, Xinsong
    Foukakis, Theodoros
    Weidler, Jodi
    Bates, Michael
    Fredriksson, Irma
    Robertson, Stephanie
    Hartman, Johan
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [25] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652
  • [26] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [27] Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer
    Wong, Nan Soon
    Ang, Peter
    Dent, Rebecca
    Lee, Soo Chin
    Lim, Siew Eng
    Khoo, Kei Siong
    Ng, Raymond
    Shih, Vivianne
    Tan, Sing Huang
    Wong, Karmen
    Yap, Yoon Sim
    Shang, Yeap
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2015, 44 (10) : 360 - 367
  • [28] Targeting HER2 in breast cancer: beyond trastuzumab
    EP Winer
    Breast Cancer Research, 13
  • [29] Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence
    Dent, R
    Clemons, M
    CANCER TREATMENT REVIEWS, 2006, 32 (02) : 144 - 148
  • [30] Targeting HER2 in breast cancer: beyond trastuzumab
    Winer, F. P.
    BREAST CANCER RESEARCH, 2011, 13
12345